Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 11, Issue 6, Pages 2273-2275Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-021-01084-4
Keywords
Molecular engineering; Cellular engineering; Immunoengineering; Immunotherapy; Drug delivery; Pharmacokinetics; Pharmacodynamics
Funding
- National Cancer Institute (NCI) [R01-CA219304, R01-CA253248]
- Chicago Biomedical Consortium via the Searle Funds at The Chicago Community Trust [CR-002]
Ask authors/readers for more resources
Immunotherapies aim to treat diseases by modulating immune cell activity, but transport barriers may hinder delivery and retention at diseased sites. Overcoming these barriers by exploiting immunobiology to engineer molecular and cellular approaches is crucial. Integrating expertise from pathologists, clinicians, immunologists, biophysicists, immunoengineers and more is essential for impactful and practical solutions across various diseases.
Immunotherapies are designed to treat disease by modulating the activity of immune cells. Here, we consider how anatomy and microphysiology create transport barriers to immunotherapeutic delivery and retention at diseased sites, and summarize recent developments to overcome these barriers by exploiting immunobiology to engineer molecular and cellular engineering approaches. Creating impactful and practical solutions across these diseases requires the integration of the collective expertise of pathologists, clinicians, immunologists, biophysicists, immunoengineers, and more.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
